Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes
Status:
Completed
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Providing more theoretical basis for the prediction of the efficacy of advanced NSCLC and
helping select better advantaged population of NSCLC immunotherapy to maximize the benefits
of patients By exploring the relationship between the changes of PD-1 expression in
peripheral blood T lymphocytes and the clinical efficacy before and after the use of PD-1 /
PD-L1 inhibitors.